Functional immune characterization of HIV-associated non-small-cell lung cancer

Affiliations

¹ Department of Surgery & Cancer, Imperial College London, Hammersmith Hospital, London, UK; National Centre for HIV Malignancies, Chelsea & Westminster Hospital, London, UK.
² Department of Surgery & Cancer, Imperial College London, Hammersmith Hospital, London, UK.
³ Department of Surgery & Cancer, Imperial College London, Hammersmith Hospital, London, UK; Department of Histopathology, Imperial College London, Hammersmith Hospital, London, UK.
⁴ National Centre for HIV Malignancies, Chelsea & Westminster Hospital, London, UK.
⁵ Department of Surgery & Cancer, Imperial College London, Hammersmith Hospital, London, UK; NIHR Blood and Transplant Research Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
⁶ National Heart and Lung Division, Imperial College London, London, UK.
⁷ Department of Histopathology, University College London, London, UK.
⁸ Department of Histopathology, Imperial College London, Hammersmith Hospital, London, UK.
⁹ Department of Genetics, Evolution and Environment & Cell and Developmental Biology, University College London, London, UK.
¹⁰ NIHR Blood and Transplant Research Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
¹¹ National Centre for HIV Malignancies, Chelsea & Westminster Hospital, London, UK. Electronic address: m.bower@imperial.ac.uk.

D J Pinato et al. Ann Oncol. 2018.

. 2018 Jun 1;29(6):1486-1488.

doi: 10.1093/annonc/mdy125.

¹ Department of Surgery & Cancer, Imperial College London, Hammersmith Hospital, London, UK; National Centre for HIV Malignancies, Chelsea & Westminster Hospital, London, UK.
² Department of Surgery & Cancer, Imperial College London, Hammersmith Hospital, London, UK.
³ Department of Surgery & Cancer, Imperial College London, Hammersmith Hospital, London, UK; Department of Histopathology, Imperial College London, Hammersmith Hospital, London, UK.
⁴ National Centre for HIV Malignancies, Chelsea & Westminster Hospital, London, UK.
⁵ Department of Surgery & Cancer, Imperial College London, Hammersmith Hospital, London, UK; NIHR Blood and Transplant Research Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
⁶ National Heart and Lung Division, Imperial College London, London, UK.
⁷ Department of Histopathology, University College London, London, UK.
⁸ Department of Histopathology, Imperial College London, Hammersmith Hospital, London, UK.
⁹ Department of Genetics, Evolution and Environment & Cell and Developmental Biology, University College London, London, UK.
¹⁰ NIHR Blood and Transplant Research Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
¹¹ National Centre for HIV Malignancies, Chelsea & Westminster Hospital, London, UK. Electronic address: m.bower@imperial.ac.uk.

No abstract available

Figures

1. Bower M, Powles T, Nelson M. et al. HIV-related lung cancer in the era of highly active antiretroviral therapy. AIDS 2003; 17(3): 371–375. - PubMed
1. Teng MW, Ngiow SF, Ribas A, Smyth MJ.. Classifying cancers based on T-cell infiltration and PD-L1. Cancer Res 2015; 75(11): 2139–2145. - PMC - PubMed
1. Taube JM, Klein A, Brahmer JR. et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res 2014; 20(19): 5064–5074. - PMC - PubMed
1. Domblides C, Antoine M, Hamard C. et al. Non-small cell lung cancer from HIV-infected patients expressed PD-L1 with marked inflammatory infiltrates. AIDS 2017; 1. - PubMed
1. Guihot A, Marcelin AG, Massiani MA. et al. Drastic decrease of the HIV reservoir in a patient treated with nivolumab for lung cancer. Ann Oncol 2018; 29(2): 517–518. - PubMed